Om

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule oncology therapies. Operating primarily in Mainland China, it concentrates on precision oncology and immuno-oncology treatments, aiming to address complex solid tumors and other cancer indications through targeted drug design. The company’s pipeline includes multiple clinical-stage and preclinical candidates, such as ABSK011 and ABSK091, which inhibit specific fibroblast growth factor receptors involved in hepatocellular carcinoma, urothelial cancer, and gastric cancer. Abbisko Cayman Limited also engages in broader pharmaceutical research and development, as well as technical and consultation services in biomedical and biotechnology fields. Its collaboration agreements with global pharmaceutical companies, including Eli Lilly and BeiGene, support co-discovery and combination therapy development, reinforcing its role in the oncology drug development ecosystem. Founded in 2016 and headquartered in Shanghai, China, Abbisko Cayman Limited today serves as a specialized R&D platform within the biotechnology and pharmaceuticals sector, contributing novel candidates to the oncology treatment pipeline.

Analytikerskøn

Baseret på 8 analytikere

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ABBISKO CAYMAN MED ENDAVU: Køb Abbisko Cayman ($2256) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Abbisko Cayman, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.